Therapeutic Areas

As a full service CRO, Emmes has worked on nearly every epidemic and pandemic since our founding in 1977, including HIV-AIDs, Zika Virus, Ebola, SARS, MERS, H1N1, and COVID-19.

Clients seek Emmes’ Ophthalmology clinical research services for a variety of disorders including age-related macular degeneration, glaucoma, diabetic retinopathy, and rare diseases.

Since 1987, clients have collaborated with Emmes on a variety of blood and marrow disorders such as lymphoma, leukemia, multiple myeloma, aplastic anemia and sickle cell anemia. We possess specialized expertise in hematopoietic stem cell transplantation (HSCT), cellular therapy and gene therapy.

Clinical trial sponsors seek Emmes to help navigate the unique challenges of maternal and child health. We have experience across a wide range of therapeutic areas, with specialized expertise in kidney and liver transplant, epilepsy, and substance use in pregnant and lactating mothers.

Clinical research on rare diseases has proliferated since the passage of the Orphan Drug Act in 1983. Emmes has helped clients conduct rare disease research across several therapeutic areas including infectious diseases, ophthalmology, oncology, autoimmune, neurology, and hematology.

Clients leverage a broad range of expertise in neurological and psychiatric disorders possessed by our Neuroscience therapeutic research unit. We have significant experience in traumatic brain injury, stroke, epilepsy, autism, depression and schizophrenia.

Use of addictive substances impacts several hundred million people worldwide. The United Nations World Drug Report 2020 estimates that in the period 2009–2018 the number of past-year users of any drug grew from 210 million to 269 million globally, representing an increase of more than 25%. Among the 269 million, 35 million suffer from drug use disorders, with one in seven being able to access treatment.